All In Biotech

NDA 017681 · Esjay Pharma

Hiprex

Methenamine Hippurate · Oral

Last checked: Nov 19, 2026Latest source record: Dec 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Sep 9, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

11

0 Phase 3, 2 recruiting

FAERS reports

1,289

736 serious, 82 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 7, 2026.

INDICATIONS & USAGE Methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 9, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • HIPREX · METHENAMINE HIPPURATE 1GM · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Methenamine Hippurate" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urinary tract infection169
  • diarrhoea83
  • drug ineffective83
  • nausea83
  • fatigue78
  • fall74
  • headache70
  • dizziness66
  • death57
  • product dose omission issue57
  • off label use52
  • pneumonia51

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
200510
20061
20071
20082
20091
20102
20115
201213
20139
201425
201552
201665
201758
201867
201972
202092
202191
202297
2023115
2024129
2025180
2026200

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 45 on PubMed

Sponsor: Esjay Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.